Full Press Release Details
Akari Therapeutics Regains Compliance with Nasdaq
Minimum Bid Price Requirement
NEW YORK and LONDON, September 5, 2023 (GLOBE NEWSWIRE) - Akari
Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases
today announced the company has received written notification from Nasdaq that it has regained compliance with the minimum bid price requirement.
The notification of compliance is a result of Akari's American Depository Shares (ADSs) having a closing bid price of $1.00 per
share or greater for 10 consecutive business days.
Akari's ADSs continue to be listed and trade on the Nasdaq Capital
Market under the symbol AKTX.
About Akari Therapeutics
Akari Therapeutics, plc (Nasdaq: AKTX) is a biotechnology company developing
advanced therapies for autoimmune and inflammatory diseases. Akari's lead asset, investigational nomacopan, is a bispecific recombinant
inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Akari's pipeline includes a Phase 3 clinical trial program
investigating nomacopan for severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). Akari has
been granted Orphan Drug, Fast Track and Rare Pediatric Disease designations from the FDA for nomacopan for the treatment of pediatric
HSCT-TMA and orphan drug designation from the European Commission for treatment in hematopoietic stem cell transplantation. Akari's
pipeline also includes a clinical program developing nomacopan for adult HSCT-TMA and pre-clinical research of long-acting PAS-nomacopan
in geographic atrophy (GA). For more information about Akari, please visit akaritx.com.
Cautionary Note Regarding Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are
based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions,
expectations, strategies, and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give
no assurance that the plans, intentions, expectations, or strategies will be attained or achieved. Furthermore, actual results may
differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that
are beyond our control. Such risks and uncertainties for our company include, but are not limited to: needs for additional capital
to fund our operations, our ability to continue as a going concern; uncertainties of cash flows and inability to meet working
capital needs; an inability or delay in obtaining required regulatory approvals for nomacopan and any other product candidates,
which may result in unexpected cost expenditures; our ability to obtain orphan drug designation in additional indications; risks
inherent in drug development in general; uncertainties in obtaining successful clinical results for nomacopan and any other product
candidates and unexpected costs that may result there; difficulties enrolling patients in our clinical trials; failure to realize
any value of nomacopan and any other product candidates developed and being developed in light of inherent risks and difficulties
involved in successfully bringing product candidates to market; inability to develop new product candidates and support existing
product candidates; the approval by the FDA and EMA and any other similar foreign regulatory authorities of other competing or
superior products brought to market; risks resulting from unforeseen side effects; risk that the market for nomacopan may not be as
large as expected risks associated with the impact of the COVID-19 pandemic; inability to obtain, maintain and enforce patents and
other intellectual property rights or the unexpected costs associated with such enforcement or litigation; inability to obtain and
maintain commercial manufacturing arrangements with third party manufacturers or establish commercial scale manufacturing
capabilities; the inability to timely source adequate supply of our active pharmaceutical ingredients from third party manufacturers
on whom the company depends; unexpected cost increases and pricing pressures and risks and other risk factors detailed in our public
filings with the U.S. Securities and Exchange Commission, including our most recently filed Annual Report on Form 20-F filed with
the SEC. Except as otherwise noted, these forward-looking statements speak only as of the date of this press release and we
undertake no obligation to update or revise any of these statements to reflect events or circumstances occurring after this press
release. We caution investors not to place considerable reliance on the forward-looking statements contained in this press
For more information